Study guide
13.4 Patent Term Extension Under 35 U.S.C. § 156
USPTO Registration Examination Patent Bar
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Overview, Registration & MPEP Structure
1.1 Patent Bar Exam Format & Administration 1.2 Practitioner Qualifications & Eligibility 1.3 MPEP Structure & Effective Search Strategies
2 Chapter 2: Subject Matter Eligibility & Utility (35 U.S.C. § 101)
2.1 Patent-Eligible Subject Matter & Statutory Categories 2.2 Judicial Exceptions & the Alice/Mayo Framework 2.3 Utility Requirements & USPTO Utility Guidelines
3 Chapter 3: Novelty & Prior Art Under the AIA (35 U.S.C. § 102)
3.1 First-Inventor-to-File (FITF) & Effective Filing Dates 3.2 The One-Year Inventor Grace Period & Exceptions 3.3 Prior Art Types & Public Availability Standards
4 Chapter 4: Nonobviousness Analysis (35 U.S.C. § 103)
4.1 The Graham Factors & KSR Obviousness Framework 4.2 Combining Prior Art References & Motivation to Combine 4.3 Overcoming § 103 Rejections & Rule 132 Affidavits
5 Chapter 5: Specification & Disclosure Requirements (35 U.S.C. § 112(a))
5.1 Written Description Requirement 5.2 Enablement Requirement & Wands Factors 5.3 Best Mode Requirement & Current Post-AIA Status
6 Chapter 6: Claim Requirements & Definiteness (35 U.S.C. § 112(b)-(f))
6.1 Definiteness & Claim Precision 6.2 Independent & Dependent Claim Construction 6.3 Special Claim Formats: Means-Plus-Function & Markush Claims
7 Chapter 7: Application Types & Filing Procedures (MPEP Chapter 600)
7.1 Provisional Patent Applications 7.2 Nonprovisional Application Parts & Formalities 7.3 Inventor Oaths, Declarations & Assignments
8 Chapter 8: Duty of Disclosure & Information Disclosure Statements
8.1 Duty of Candor & Good Faith 8.2 Information Disclosure Statements (IDS) Requirements 8.3 Correcting Non-Disclosure & Duty Compliance
9 Chapter 9: Patent Prosecution & Office Action Responses (MPEP Chapter 700)
9.1 Initial Examination & Non-Final Office Actions 9.2 Statutory Deadlines & Extension of Time 9.3 Final Office Actions & Post-Final Practice
10 Chapter 10: Continuing Applications & Copendency
10.1 Continuation Applications 10.2 Divisional Applications 10.3 Continuation-in-Part (CIP) Applications & Priority Allocation
11 Chapter 11: Appeals & Interferences/Derivation (MPEP Chapter 1200 & 2300)
11.1 Ex Parte Appeals to the PTAB 11.2 PTAB Appeal Decisions & Judicial Review 11.3 Derivation Proceedings Under the AIA
12 Chapter 12: Post-Grant Proceedings & Corrections (MPEP Chapters 1400 & 2200)
12.1 Reissue Applications & Certificates of Correction 12.2 Ex Parte Reexamination & Supplemental Examination 12.3 Inter Partes Review (IPR) & Post-Grant Review (PGR)
13 Chapter 13: Patent Term, Maintenance Fees & Ownership
13.1 Patent Term Calculation & Patent Term Adjustment (PTA) 13.2 Maintenance Fees & Expiration 13.3 Inventorship, Ownership & Assignment Recordation 13.4 Patent Term Extension Under 35 U.S.C. § 156
14 Chapter 14: International Patent Practice & PCT (MPEP Chapter 1800)
14.1 The Patent Cooperation Treaty (PCT) Overview 14.2 PCT International Phase & Chapter I / Chapter II 14.3 National Phase Entry Under 35 U.S.C. § 371
15 Chapter 15: Special Patent Categories & Professional Conduct
15.1 Design Patents & Plant Patents 15.2 USPTO Rules of Professional Conduct 15.3 Patent Bar Exam Strategy & Open-Book Navigation Tips
16 Chapter 16: Security, Access, Representation & Filing Mechanics
16.1 Secrecy, Application Access & Foreign Filing Licenses 16.2 Representation, Power of Attorney & Correspondence 16.3 Filing Receipt, Certificates of Transmission & Signatures
17 Chapter 17: Restriction, Publication, Allowance & Office Authority
17.1 Restriction, Election, Rejoinder & Double Patenting 17.2 Publication, Preissuance Submissions & Protests 17.3 Allowance, Issue Fee & Withdrawal from Issue 17.4 Examiner Interviews, Petitions & Office Authority
18 Chapter 18: Biotechnology Disclosure & Patent Prosecution Highway
18.1 Biological Deposits & Sequence Listings 18.2 Global/IP5 Patent Prosecution Highway
19 Chapter 19: AIA Trial Practice Under the Consolidated Guide
19.1 AIA Trial Petitions, Preliminary Response & Institution 19.2 AIA Trial Discovery, Motions, Hearing & Final Decision
13.4 Patent Term Extension Under 35 U.S.C. § 156
Key Takeaways Explain This Topic AI
Patent term extension under 35 U.S.C. § 156 compensates an eligible product patent for part of the time consumed by a qualifying federal regulatory review period; it is distinct from patent term adjustment under § 154(b).
The patent must be unexpired, must not previously have been extended under § 156, and must claim the approved product, a method of using it, or a method of manufacturing it.
The patent owner or authorized agent ordinarily must apply within 60 days of the first permitted commercial marketing or use of the product.
The calculated extension is reduced for periods before patent issuance, overlap, and lack of due diligence, and is subject to a five-year extension cap and a fourteen-year post-approval cap.
Last updated: August 2026
- 13.4 Patent Term Extension Under 35 U.S.C. § 156
- Three different term concepts
Patent-term questions often place three separate rules in one fact pattern. The ordinary term for a modern utility or plant patent generally runs twenty years from the controlling nonprovisional filing date, subject to statutory qualifications. Patent term adjustment (PTA) under 35 U.S.C. § 154(b) adds days for specified USPTO examination delays, net of applicant delay and overlap. Patent term extension (PTE) under 35 U.S.C. § 156 instead restores part of the time lost while a patented product undergoes a qualifying federal regulatory review before commercial marketing or use.
The distinction controls which facts matter. An examiner delay points toward PTA. Food and Drug Administration or other qualifying agency review points toward PTE. Maintenance fees and terminal disclaimers are separate issues and should not be used as substitutes for either calculation.
Eligible patents and products
Section 156 applies to specified human drug products, animal drug products, medical devices, food additives, and color additives that were subject to a regulatory review period before their first permitted commercial marketing or use. For an application to qualify:
the patent must claim the approved product, a method of using the product, or a method of manufacturing the product;
- the patent must not have expired before the application is submitted;
- the patent must not previously have received an extension under § 156;
- the approved product must have been subject to a qualifying regulatory review period; and
the permission relied upon generally must be the first permitted commercial marketing or use of that product under the governing provision of law.
Only one patent may be extended for the same regulatory review period. When more than one patent could cover the product, the owner must make the statutory election rather than obtain cumulative extensions. The application is made by the patent owner of record or its authorized agent and must identify the patent, approved product, approval date, regulatory review history, and the manner in which the claims cover the product or an approved use or manufacturing method.
The sixty-day application period
The ordinary filing period is 60 days beginning on the date the product first receives permission for commercial marketing or use . This is a statutory deadline, so ordinary prosecution extensions under Rule 1.136 do not rescue a late PTE application. The statute contains a special rule for approvals transmitted after 4:30 p.m. Eastern Time: for purposes of determining the first permitted marketing date, the approval is treated as occurring on the next business day. On an exam, use the facts given and calculate the window under § 156(d), not an Office-action response rule.
An applicant may need an interim extension when a patent will expire while regulatory review or the PTE determination is still pending. Interim relief has its own conditions and does not eliminate the need for a timely complete application.
Calculating and limiting the extension
The regulatory review period is divided into a testing phase and an approval phase. In simplified form, the statutory calculation counts one-half of the qualifying testing phase plus the qualifying approval phase . The USPTO and regulatory agency then apply important reductions:
- time in the regulatory review period that occurred before the patent issued is excluded;
- overlapping calendar days are not counted twice;
- periods during which the applicant did not act with due diligence are subtracted; and
the remaining result is constrained by the statutory caps.
The extension itself cannot exceed five years . In addition, the patent term remaining after regulatory approval, including the extension, ordinarily cannot exceed fourteen years . Thus a raw regulatory-review calculation of six years is capped at five, and even a five-year result can be reduced further if it would leave more than fourteen years of patent life after approval.
Agency roles, diligence, and scope during extension
The regulatory agency supplies the review-period dates and publishes them for public inspection; the USPTO decides patent eligibility and the ultimate extension. An interested person may petition for a due-diligence determination under the applicable procedure. The owner must respond accurately because an unexplained interval in testing or approval work can reduce the extension.
During the extended period, enforceable scope is limited by § 156(b) to the approved product and permitted uses in the manner specified by the statute. PTE does not convert every claim in the patent into a broader monopoly. For a method-of-use claim, attention to the approved use matters; for a product claim, attention to the statutory definition of product matters.
Exam checklist
When a term problem mentions regulatory approval, ask in order:
- Question Why it matters
- Is the patent unexpired and never previously extended? Basic patent eligibility
- Does a claim cover the approved product, use, or manufacture? Required claim relationship
- Is this the first permitted commercial marketing or use? Product eligibility
- Was the application filed within 60 days? Statutory filing gate
- What portions of testing and approval count? Base calculation
- Are there pre-issuance days, overlap, or lack of diligence? Mandatory reductions
- Do the five-year and fourteen-year caps reduce the result? Final ceiling
Keeping that sequence separate from PTA prevents the most common category error: awarding regulatory-review time under the USPTO-delay formula or using the seven-year maximum PTA shorthand as a PTE rule.